WHAT IS SCHIZOPHRENIA?

Schizophrenia is a complex multifaceted mental illness that features psychotic, negative, affective and cognitive symptoms. Sufferers deal with anxiety, depression, attention deficit and low motivation.

In European Union approximately 5 million people suffer from psychotic disorders.

Between 30% and 50% of people suffering from schizophrenia are treatment-resistant cases.

High suicide risk and low insight are characteristic symptoms.

Refractory Schizophrenia means:

- Higher emotional distress
- Highly persistent symptoms
- Long periods of hospital attention
- Greater risk of mortality and multi morbidity

“We hope that m-RESIST will bring a real benefit for people with treatment-resistant schizophrenia by extending the area of application of the personalized pharmacological and psychological treatment, not only improving the persistence of care and the participation of the caregivers, but also by creating a broad database to allow development in characterising the profile of the people with treatment-refractory schizophrenia”.

The m-RESIST Clinical Team

This project is co-funded by the Horizon 2020 Framework Programme of the European Union under grant agreement no [843552].
Standard treatment is not sufficient enough
Find new means of treating this severe brain disorder which cause marked impairments in social, occupational, and cognitive functioning.

WHAT m-RESIST AIMS TO OFFER?

- Model of analysis to move forward in understanding treatment-resistant schizophrenia
- Innovative Disease Management System
- Mobile ICT system addressed to empower Patients and caregivers

THE m-RESIST APPROACH:

- Optimise & personalise patient’s treatment, ensuring immediacy and continuity of care and improve current healthcare processes
- Use of m-RESIST integrated care program
- Use of Big Data mining tools
- Use of Predictive model

BY

actively participating in the therapeutic process & self-managing their condition

TARGET AUDIENCES

- The patients
- Their families
- The clinicians

THE m-RESIST STEP BY STEP

- The innovative disease management system consists of different parts of development
- Designing and developing the m-RESIST system
- Designing the m-RESIST program (services, care pathways or health routes)
- Testing the m-RESIST system & program on healthy volunteers, patients and caregivers
- Promoting the active role of patients, caregivers, clinicians in the design & assessment of the m-RESIST program & tools
- Creating a predictive model to identify risks & gaps in the treatments enabling the prescription of personalized treatment & tools for patients

The collaboration of caregivers, patient’s families and professionals would enable the provision of specific support services and would prevent acute symptoms.

THE m-RESIST

BY

Mobile ICT system addressed to empower Patients and caregivers

Model of analysis to move forward in understanding treatment-resistant schizophrenia

Innovative Disease Management System

Mobile ICT system

The patients

Their families

The clinicians

Testing the m-RESIST system & program on healthy volunteers, patients and caregivers

Promoting the active role of patients, caregivers, clinicians in the design & assessment of the m-RESIST program & tools

Creating a predictive model to identify risks & gaps in the treatments enabling the prescription of personalized treatment & tools for patients

Designing and developing the m-RESIST system

Designing the m-RESIST program (services, care pathways or health routes)